Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Soleno Therapeutics, Inc. (SLNO) had Revenue of $66.02M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$66.02M
Net Income	$26.01M
Cost of Goods Sold	$1.14M
Gross Profit	$64.88M
Operating Expenses	$43.91M
Operating Income	$22.11M
Non-Operating Income/Expense	$3.91M
Pre-Tax Income	$26.01M
Normalized Pre-Tax Income	$26.01M
Income after Taxes	$26.01M
Income from Continuous Operations	$26.01M
Consolidated Net Income/Loss	$26.01M
Normalized Income after Taxes	$26.01M
EBIT	$22.11M
EBITDA	$22.62M
Weighted-Average Shares Outstanding (Basic)	53.33M
Weighted-Average Shares Outstanding (Diluted)	54.92M
Earnings per Share (EPS) (Basic)	$0.49
Earnings per Share (EPS) (Diluted)	$0.47
Balance Sheet Financials
Current Assets	$534.85M
Property, Plant, and Equipment	$0.15M
Long-Term Assets	$65.04M
Total Assets	$599.89M
Current Liabilities	$33.25M
Long-Term Debt	$49.85M
Long-Term Liabilities	$71.84M
Total Liabilities	$105.09M
Common Equity	$494.81M
Tangible Shareholders Equity	$489.46M
Shareholders Equity	$494.81M
Common Shares Outstanding	53.70M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-1.91M
Cash Flow from Investing Activities	$-76.42M
Cash Flow from Financial Activities	$237.06M
Beginning Cash	$87.93M
End Cash	$246.66M
Increase/Decrease in Cash	$158.73M
Stock-Based Compensation	$34.38M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	16.08
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.09
Debt to Equity Ratio	0.10
Gross Margin	98.27%
Operating Margin	33.48%
EBIT Margin	33.48%
EBITDA Margin	--
Pre-Tax Profit Margin	39.40%
Profit Margin	39.40%
Free Cash Flow	$-1.92M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.11
Inventory Turnover	0.17
Receiveable Turnover	2.59
Days Sales in Receivables	34.77
Return on Equity	5.26%
Return on Tangible Equity	5.31%
Return on Assets	4.34%
Return on Investments	4.78%
Book Value Per Share	$9.21
Free Cash Flow per Share	$-0.04
Operating Cash Flow per Share	$-0.03

Data from Zacks Investment Research, Inc.